An encouraging experimental drug that is being developed for Multiple Sclerosis continues to show promise in being able to offer neuroprotective benefits — an effect that could slow and eventually cure MS. Masitinib, which is being developed by AB Science for numerous neurological indications, including Alzheimer’s disease, progressive multiple sclerosis, and amyotrophic lateral sclerosis (ALS), is now showing signs of being able to offer neuroprotection in stroke as well.
Stroke, both ischemic and hemorrhagic, is the second-leading cause of mortality worldwide and currently lacks effective treatments, leading to very poor prognosis to those who have been affected. Stroke, or cerebrovascular accident (CVA) is caused by abnormal blood supply, either lack of blood flow — ischaemic — or hemorrhage. The current treatments for ischaemic stroke include measures to lower blood pressure, reducing cerebral edema, temperature control, glucose regulation, and antiplatelet and fibrinolytic treatments. Recently, a new strategy for treating experimentally induced ischemic stroke in mice and rats were proposed with neuro protection as the underlying principle.
~~~~~~~~~~~~~~~~~~~~
Keep CURRENT and up to date,
with MS Views and News – OPT-IN here
.
.
.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
